Objective

The task force’s goal is to provide recommendations on reporting and evaluating the risk of bias of systematic reviews with cost or cost-effectiveness outcomes. The recommendations will serve for reviews with various objectives (variability in outcomes, quality of evidence or methods, or research gaps estimation) and will be applicable to summaries of economic evidence assessed either independently or within clinical reviews.

Rationale

The task force report will fill a gap in guidance on assessing the reporting and risk of bias in systematic reviews with cost and cost-effectiveness outcomes and propose a checklist for reviews of varying scope.  With the increasing interest in systematic reviews of economic evaluations, and the current lack of an appropriate instrument to evaluate and judge their quality, there is a significant need for ISPOR good practices on this topic.  It is a priority for the health technology assessment (HTA) field and its respective stakeholders. 

These recommendations and checklist will be important for decision makers, researchers, and producers of health technologies.  The growing number of systematic reviews with an economic component provides coherent evidence on cost-effectiveness outcomes.  However, the diversity of methods and outcomes of these reviews make it difficult for decision makers to use this summarized information most effectively. 

Researchers can improve the reporting and quality of their study and to evaluate reporting and quality of systematic reviews conducted by other teams. Emerging systematic reviews with cost and cost-effectiveness components may guide producers of health technologies on pricing, resource allocation, and economic models, ultimately contributing to market access strategies conditional on the premise that the quality of these reviews is trustworthy.

Co-Chairs

Jeremy Goldhaber-Fiebert

Jeremy Goldhaber-Fiebert

Associate Professor of Medicine, Core Faculty Member, Centers for Health Policy and Primary Care and Outcomes Research (CHP/PCOR), Stanford University
Stanford, CA, United States
Lena Mandrik

Lena Mandrik, MSc MPH

Research Fellow, University of Sheffield
Sheffield, YOR, Great Britain
JL Severens

JL Severens, PhD

Dean, School of Health Policy and Management, Erasmus University Rotterdam
Rotterdam, ZH, Netherlands

Leadership Group

Ariel Bardach, MSc PhD MD

Researcher, Health Technology Assessment (HTA) and Health Economic Evaluations Department, IECS - Instituto de Efectividad Clínica y Sanitaria Asociación Civil
Buenos Aires, Argentina

Salah Ghabri, PhD MD

Health Economist/Project coordinator, French National Authority for Health (HAS)
Saint-Denis La Plaine, France

Candyce Hamel

Senior Clinical Research Associate, Clinical Epidemiology Program, Ottawa Hospital Research Institute
Ottawa, Canada

Cristina Masseria, MSc PhD

Methods and Capabilities Lead, Patient & Health Impact (PHI), Pfizer
New York, NY, United States

Tim Mathes

Research Associate, Institute for Research in Operative Medicine (IFOM),, Witten / Herdecke University,
Cologne, Germany

Luke Vale

Health Foundation Chair in Health Economics, and Deputy Director, Institute of Health & Society,, Newcastle University
Newcastle, NBL, United Kingdom

Torbjørn Wisløff, MSc MASc BSc

Senior statistician, NOKC
Oslo, Norway
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×